PT1200117E - Tratamento à base de variantes da lipoproteína lipase - Google Patents

Tratamento à base de variantes da lipoproteína lipase Download PDF

Info

Publication number
PT1200117E
PT1200117E PT00943499T PT00943499T PT1200117E PT 1200117 E PT1200117 E PT 1200117E PT 00943499 T PT00943499 T PT 00943499T PT 00943499 T PT00943499 T PT 00943499T PT 1200117 E PT1200117 E PT 1200117E
Authority
PT
Portugal
Prior art keywords
lpl
vol
therapeutic
nucleic acid
protein
Prior art date
Application number
PT00943499T
Other languages
English (en)
Portuguese (pt)
Inventor
Michael R Hayden
John J P Kastelein
Katherine Julia Diane Excoffon
Original Assignee
Univ British Columbia
Amsterdam Molecular Therapeutics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia, Amsterdam Molecular Therapeutics Bv filed Critical Univ British Columbia
Publication of PT1200117E publication Critical patent/PT1200117E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18Carboxylic ester hydrolases (3.1.1)
    • C12N9/20Triglyceride splitting, e.g. by means of lipase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y301/00Hydrolases acting on ester bonds (3.1)
    • C12Y301/01Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01034Lipoprotein lipase (3.1.1.34)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
PT00943499T 1999-06-24 2000-06-23 Tratamento à base de variantes da lipoproteína lipase PT1200117E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99202048 1999-06-24

Publications (1)

Publication Number Publication Date
PT1200117E true PT1200117E (pt) 2008-11-26

Family

ID=8240356

Family Applications (1)

Application Number Title Priority Date Filing Date
PT00943499T PT1200117E (pt) 1999-06-24 2000-06-23 Tratamento à base de variantes da lipoproteína lipase

Country Status (12)

Country Link
US (1) US20110201673A1 (https=)
EP (1) EP1200117B1 (https=)
JP (1) JP5095894B2 (https=)
AT (1) ATE404217T1 (https=)
AU (1) AU5799200A (https=)
CA (1) CA2370081C (https=)
CY (1) CY1108511T1 (https=)
DE (1) DE60039880D1 (https=)
DK (1) DK1200117T3 (https=)
ES (1) ES2311464T3 (https=)
PT (1) PT1200117E (https=)
WO (1) WO2001000220A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE437657T1 (de) * 2004-03-02 2009-08-15 Cellectar Inc Phospholipid-analoga für die behandlung von krebs
PT1761273E (pt) * 2004-06-21 2008-10-28 Amsterdam Molecular Therapeutics Bv Tratamento da esteatohepatite não alcoólica (nash)
EP2311966A3 (en) 2005-10-20 2012-09-05 Amsterdam Molecular Therapeutics (AMT) B.V. Improved AAV vectors produced in insect cells
CN103849629B (zh) 2006-06-21 2017-06-09 尤尼克尔Ip股份有限公司 具有经修饰的用于在昆虫细胞中产生aav的aav‑rep78翻译起始密码子的载体
DK2173888T3 (en) 2007-07-26 2016-11-28 Uniqure Ip Bv Baculovirus vectors comprising repeating coding sequences WITH differential preferred codons
WO2009030254A1 (en) * 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
EP2432497A1 (en) * 2009-05-18 2012-03-28 Amsterdam Molecular Therapeutics (AMT) IP B.V. Use of lipoprotein lipase (lpl) in therapy
JP6092624B2 (ja) 2009-06-12 2017-03-08 セレクター,インコーポレイティド 癌の治療並びに癌幹細胞の造影および検出のためのエーテルおよびアルキルリン脂質化合物
EP2545165B1 (en) 2010-03-11 2020-07-29 uniQure IP B.V. Mutated rep encoding sequences for use in aav production
WO2011122950A1 (en) 2010-04-01 2011-10-06 Amsterdam Molecular Therapeutics (Amt) Ip B.V. Monomeric duplex aav vectors
JP6188728B2 (ja) 2012-02-07 2017-08-30 グローバル・バイオ・セラピューティクス・インコーポレイテッドGlobal Bio Therapeutics,Inc. 核酸送達の区画化方法ならびにその組成物および使用
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
CA2942289C (en) 2014-03-10 2024-05-21 Uniqure Ip B.V. Further improved aav vectors produced in insect cells
MA41035A (fr) * 2014-08-19 2017-08-15 Shire Human Genetic Therapies Lipoprotéine lipase pour le traitement d'affections liées à une hypertriglycéridémie, y compris la pancréatite aiguë
US12123030B2 (en) 2016-05-18 2024-10-22 Modernatx, Inc. Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia
WO2018109207A1 (en) 2016-12-16 2018-06-21 Uniqure Ip B.V. Immunoadsorption
JP7764129B2 (ja) 2017-07-10 2025-11-05 ユニキュアー アイピー ビー.ブイ. ヒトにおけるaav遺伝子療法のための手段及び方法
EP3655538A1 (en) 2017-07-20 2020-05-27 uniQure IP B.V. Improved aav capsid production in insect cells
WO2019129859A1 (en) 2017-12-29 2019-07-04 Uniqure Ip B.V. Modified viral vectors and methods of making and using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2188675A1 (en) * 1994-04-11 1995-10-19 Savio L. C. Woo Compositions and methods for gene therapy to treat disease
US5658729A (en) * 1994-10-11 1997-08-19 The University Of British Columbia Method, reagent and kit for evaluating susceptibility to premature atherosclerosis

Also Published As

Publication number Publication date
CY1108511T1 (el) 2014-04-09
EP1200117B1 (en) 2008-08-13
CA2370081C (en) 2014-06-03
US20110201673A1 (en) 2011-08-18
WO2001000220A3 (en) 2001-07-12
EP1200117A2 (en) 2002-05-02
DK1200117T3 (da) 2008-11-17
DE60039880D1 (en) 2008-09-25
ATE404217T1 (de) 2008-08-15
JP5095894B2 (ja) 2012-12-12
WO2001000220A2 (en) 2001-01-04
JP2003503355A (ja) 2003-01-28
CA2370081A1 (en) 2001-01-04
ES2311464T3 (es) 2009-02-16
AU5799200A (en) 2001-01-31

Similar Documents

Publication Publication Date Title
US20110201673A1 (en) Lpl variant therapeutics
Jimenez et al. FGF21 gene therapy as treatment for obesity and insulin resistance
EP2441770A1 (en) Phosphatase inhibitor protein-1 as a regulator of cardiac function
JP2009539844A (ja) Sirt1およびlxrのコレステロール制御複合体ならびに使用法
JP2015503924A (ja) 遺伝子導入のための方法及び組成物
Burks et al. Angiopoietin-like 3: an important protein in regulating lipoprotein levels
US12371462B2 (en) Brown fat-selective adipokines
US20110081332A1 (en) Treatment of non-alcoholic steatotic hepatitis (nash)
US20020082204A1 (en) Treatment of inflammation with p20
AU2001253233B2 (en) Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia
US9290751B2 (en) LPL variant therapeutics
US10835620B2 (en) Methods for treating heart failure using beta-ARKnt peptide
WO2021216701A1 (en) Compositions for treatment of vascular disease
KR20220133900A (ko) 점액다당류증 iva의 치료
FI120154B (fi) Yhdistelmä-DNA-viruksia, niitä sisältävä farmaseuttinen koostumus, niillä tartutettu nisäkässolu ja soluja sisältävä istute
US7309606B2 (en) Methods and compositions for treating hypercholesterolemia
ES2252032T3 (es) Modulacion de angiogenesis usando angiotensina-7 antiangiogenica y polinucleotidos codificantes para dicha sustancia para el tratamiento de tumores.
HK1124614A (en) Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia